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Strengths and limitations of this study
 ► This will be the first trial to evaluate the effective-
ness of protocolled practice nurse-led care for chil-
dren with asthma in primary care.
 ► Asthma in children is a clinical diagnosis for which 
no ‘gold standard’ diagnostic criteria are avail-
able.‘Physician-diagnosed asthma’ will be used as 
an inclusion criterium in this trial.
 ► Primary outcome will be asthma control during the 
18 month follow-up measured by the Childhood 
Asthma Control Test. This questionnaire shows good 
agreement as compared with the Global Initiative for 
Asthma criteria.
AbStrACt
Introduction In children with asthma, daily symptoms 
and exacerbations have a significant impact on the 
quality of life of both children and parents. More 
effective use of asthma medication and, consequently, 
better asthma control is advocated, since both 
overtreatment and undertreatment are reported in 
primary care. Trials in adults suggest that asthma 
control is better when patients receive a regular medical 
review. Therefore, protocolled care by the general 
practitioner may also lead to better asthma control in 
children. However, such protocolled care by the general 
practitioner may be time consuming and less feasible. 
Therefore, this study aims to determine whether 
protocolled practice nurse-led asthma care for children 
in primary care provides more effective asthma control 
than usual care.
Methods and analysis The study will be a cluster-
randomised open-label trial with an 18-month follow-
up. Practice nurses will be the units of randomisation 
and children with asthma the units of analysis. It is 
planned to include 180 children aged 6–12 years. 
Primary outcome will be average asthma control during 
the 18-month follow-up measured by the Childhood 
Asthma Control Test (C-ACT). Secondary outcomes 
include C-ACT scores at t=3, t=6, t=12 and t=18 
months; the frequency and severity of exacerbations; 
cost-effectiveness; quality of life; satisfaction with 
delivered care; forced expiratory volume in 1 s and 
forced expiratory flow at 75% and the association 
of high symptoms scores at baseline and baseline 
characteristics. Besides, we will conduct identical 
measurements in a non-randomised sample of children.
Ethics and dissemination This will be the first trial to 
evaluate the effectiveness of protocolled practice nurse-
led care for children with asthma in primary care. The 
results may lead to improvements in asthma care for 
children and can be directly implemented in revisions of 
asthma guidelines.
The study protocol was approved by the Medical Research 
Ethics Committee of the Erasmus Medical Centre in 
Rotterdam.
trial registration NTR6847.
IntroduCtIon
Epidemiology and burden of disease
Asthma is the most common chronic disease 
in children in primary care in the Netherlands 
with annual prevalences ranging from 3.0% 
to 6.5%.1 A Dutch study on the prevalence 
of atopic disorders reported that 6.1% of 
the children aged 0–18 years had asthma.2 
The symptoms include recurrent episodes of 
wheeze, cough and breathlessness.3 Asthma in 
children is associated with significant comor-
bidity, for example, other airway symptoms 
and/or (infectious) diseases.4 Moreover, the 
symptoms may have a considerable impact on 
the quality of life of children with asthma and 
their parents, as well as on healthcare costs. 
For example, in the Netherlands in 2015, 
the total costs of airway diseases for children 
aged ≤15 years were estimated at 312.9 million 
euros and healthcare costs for primary care 
for this patient category were 53.6 million 
euros per year.5
Healthcare system
In the Dutch healthcare system, the general 
practitioner (GP) has a key role and (almost) 
everyone is registered with a GP practice. The 
diagnosis and treatment of asthma, also in 
children, are part of general practice. In case 
of diagnostic or treatment problems in chil-
dren with asthma, referral to secondary care 
is possible. However, referral to, for example, 
a paediatrician or paediatric pulmonologist 
requires prior consent from a GP.
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treatment
Inhaled corticosteroids (ICS) may be prescribed to reduce 
the chronic inflammatory condition of the lungs. ICS are 
the basis of treatment when symptoms are severe enough 
to justify maintenance treatment, for example, when symp-
toms occur more than twice a week. Intermittent symp-
toms of asthma are treated with bronchodilators, starting 
with a short-acting beta agonist (SABA).6 7 In some cases 
of acute severe symptoms of dyspnoea (ie, asthma exacer-
bation), oral prednisone may be considered.5
According to the guideline of the Dutch College of 
General Practitioners, the goal of asthma treatment is to 
achieve the best possible asthma control.6 In case of medi-
cation use, the aim is to use the lowest dose/frequency 
possible to achieve this goal.6 However, there are strong 
indications that underdiagnosis and overdiagnosis8–10 (or 
too frequent registration of the diagnosis) and under-
treatment and overtreatment11 are present in Dutch 
general practice.12 In a large Dutch cohort study, 30% of 
the children at the age of 8 years with self-reported ‘severe 
current asthma symptoms’ were not using ICS (probable 
undertreatment).11 Undertreatment can result in unnec-
essary symptom burden, impaired asthma control and 
more frequent exacerbations.13 On the other hand, up 
to 50% of children with ICS for at least 2 years did not 
report any wheezing during those 2 years, that is possible 
overtreatment).11 Overtreatment may lead to increased 
healthcare costs and potential iatrogenic effects of the 
medication.
Protocolled care and review visits
A recent qualitative study demonstrated that there is a 
need for an intervention to help parents optimise the 
management of childhood asthma.14 Research among 
children from primary and secondary care diagnosed 
with moderately severe asthma and treated with ICS 
showed impaired asthma control at 1-year follow-up and 
less planned review visits for the children in general 
practice, as compared with children who were treated in 
secondary care.15
Protocolled care by the GP may lead to better asthma 
treatment in children. Moreover, it seems to be feasible, 
since two widely supported evidence-based guidelines are 
available in the Netherlands for asthma care in children 
in primary care: (1) the GP guideline for asthma in chil-
dren developed by the Dutch College of General Prac-
titioners in 2014, which provides guidance for diagnosis 
and management of (suspected) asthma in children6 and 
(2) the care guideline for asthma in children developed 
by the ‘Lung Alliance Netherlands’ in 2012.16 These two 
guidelines recommend planned reconsultations with 
structured evaluation of individual care plans and gained 
goals, allowing to make alterations in the management of 
the child’s asthma more proactively. Unfortunately, in the 
Netherlands, regular follow-up of children with asthma, as 
prescribed in these guidelines, is poorly implemented.12
International guidelines promote both a policy of 
optimal symptom control and a focus on prevention of 
symptom worsening in the subsequent months (‘risk 
factors for poor outcome’).17 With regard to asthma, a 
systematic review found no significant difference between 
hospital-based nurse-led care for patients with asthma 
compared with physician-led care.18 However, the review 
included a relatively small number of studies and further 
research was recommended. Moreover, only two rela-
tively small studies of the (in total) five included studies 
concerned asthma in children and both of these studies 
evaluated care by hospital-based specialised asthma 
nurses; therefore, extrapolation of the results to primary 
care is insufficiently supported.19 20
The results of an Australian cluster randomised 
controlled trial (RCT) with 195 patients showed that 
regular spirometry with medical review was associated 
with improved asthma control in adolescent and adult 
patients.21 The authors of a Cochrane review (2003) 
demonstrated that regular medical review improved 
healthcare outcomes when combined with education 
in self-management for adults with asthma.22 Although 
regular review visits are needed, this is time consuming 
and may be less feasible for GPs in primary care.
Practice nurse-led care
In the Netherlands, the majority of GP practices have prac-
tice nurses (otherwise known as general practice-based 
nurse practitioners or physician assistants; hereafter, 
referred to as ‘practice nurses’) whose main task is to 
perform structured diabetes and cardiovascular risk 
management and care for patients with chronic obstruc-
tive pulmonary disease. This care is supervised by the GPs. 
In primary care, management of diabetes mellitus can be 
safely transferred to practice nurses.23 24 Protocolled care 
for children with asthma in general practice, supplied by a 
practice nurse and under supervision of the GP, may give 
similar (or even better) results in asthma care. However, 
as shown by a systematic review, there is limited evidence 
of efficacy for primary care based asthma clinics, and firm 
conclusions cannot be formed until more good quality 
trials have been carried out.25 Furthermore, the (cost-)
effectiveness of protocolled asthma management for chil-
dren in primary care by a trained practice nurse has not 
yet been evaluated.
Aim of the study
The aim of this study is to determine the effectiveness 
of protocolled nurse-led asthma care for children aged 
6–12 years in primary care as compared with usual care. 
The overall aim is to improve asthma care for children in 
primary care. This will be measured by determining the 
average asthma control during the 18-month follow-up, 
as measured by the Childhood Asthma Control Test 
(C-ACT). Besides improvement for individual children, 
this may lead to a reduction of the social burden of the 
disease. Physician-nurse substitution, with a special focus 
on ‘proactive care’, may reduce healthcare costs while 
maintaining quality of care.
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Figure 1 Flowchart of the study design. GP, general practitioner; ICS, inhaled corticosteroids; ICPC, International Classification 
of Primary Care.
MEtHodS/dESIgn
design
The aim is to conduct a cluster RCT with a follow-up of 
18 months. Recruited practice nurses (or groups of prac-
tice nurses) representing one cluster will be randomised 
into one of the two arms: (1) protocolled nurse-led care 
or (2) ‘usual care’ by the GP. During the study, a number 
of potential participating GPs were already intending to 
start protocolled nurse-led care for children with asthma 
in their practice. Because of this reason, we decided to 
enable these health centres to participate in the non-ran-
domised part of the trial. This new sample was added 
after the study started and the change was approved by 
the ethics committee. All measurements and study proce-
dures (except for the randomisation) will be identical to 
the randomised group of patients. Figure 1 is a flowchart 
of the study design.
Patients
All children aged 6–12 years with asthma registered in 
the GP practices involved will be invited to participate. 
Patients are eligible if they fit the following inclusion and 
exclusion criteria.
Criteria for inclusion
 ► Age 6–12 years and with one or more of the following 
criteria.
 ► Patients who were prescribed an ICS one or more 
times in the previous year.
 ► Patients who were prescribed salbutamol or terbu-
taline two or more times in the previous year.
 ► Children with only one prescription of salbutamol or 
terbutaline in the previous year and a registered Inter-
national Classification of Primary Care (ICPC) code 
for asthma (R96) or R29.02 ‘Prikkelbare Luchtwegen’ 
(bronchial spasm).
Criteria for exclusion
 ► Children receiving asthma treatment from secondary 
care, with secondary care being the main provider of 
asthma care.
 ► Children who are not able to perform lung function 
tests.
 ► Children with other major chronic diseases which 
are treated in secondary care; however, children with 
atopic conditions such as eczema or allergies are not 
excluded, since these are prevalent comorbidities.
 ► Children whose parents are unable to under-
stand verbal Dutch instructions or written Dutch 
questionnaires.
Primary outcome measure
The primary outcome measure is the average asthma 
control over 18 months measured by the C-ACT.26 27
The C-ACT is a seven-item questionnaire (with a recall 
window of 4 weeks) that addresses three questions for 
parents and four questions for children and has been 
validated in children aged 4–11 years.27 The C-ACT 
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questionnaire will be filled out at baseline and at four 
specified times during the trial. The average C-ACT score 
will be determined using the measurements on baseline 
and 3, 6, 12 and 18 months.
Secondary outcome measures
1. C-ACT outcomes at 3, 6, 12 and 18 months.
2. Frequency and severity of exacerbations. Exacerbations 
of asthma are episodes characterised by a progressive 
increase in asthma symptoms, that is, they represent a 
change from the patient’s usual status that is sufficient 
to require a change in treatment. This will be deter-
mined by a questionnaire filled out by the parents.
3. Generic health-related quality of life at 3, 6, 12 and 18 
months. This will be measured by the Child Health 
Utility 9D (CHU9D)28 and the EuroQol 5D-5L-Y (EQ-
5D-Y).29 Both instruments were specifically designed 
for use in children.
4. Direct and indirect healthcare costs. The parents will 
be asked to record healthcare resource use and ab-
sence from paid work in diaries. Hospital costs will be 
assessed by a retrospective chart review at 18 months 
and by a questionnaire to the parents of the patients.
5. Cost-effectiveness and cost-utility.
6. Disease-specific quality of life measured by the Stan-
dardised Paediatric Asthma Quality of Life Ques-
tionnaire (PAQLQ(S)) at baseline and at 6 and 18 
months.30
7. Patient/parent/nurse/GP satisfaction with delivered 
care. The questionnaire consists of one statement: 
‘Overall, I am satisfied with current asthma care by my 
GP practice’. The Likert scale will be as follows: strong-
ly disagree, somewhat disagree, neither agree nor dis-
agree, somewhat agree, or strongly agree.
8. Spirometry: forced expiratory volume in 1 s (FEV1), 
forced expiratory flow at 75% of vital capacity (FEF 75) 
and reversibility at baseline and at t=18 months.
9. Medication use in the intervention and control group, 
measured by a questionnaire.
Intervention (a protocol for nurse-led care)
For this study, we summarised the guidelines of the Dutch 
College of General Practitioners and the care guideline 
for asthma in children, into one concise and easy-to-use 
protocol for practice nurses. This protocol encompasses 
an integral assessment of the patient, concerning: patient 
history, analyses of physical parameters, experienced 
complaints and restrictions, quality of life, investigation 
of the possible presence of allergy and determination 
of the expectations of the patient and their parents with 
regard to healthcare providers.
In addition, the protocol will contain education about 
asthma for the child and the parent, guidance on non-phar-
macological interventions (eg, lifestyle advice, guidance 
on physical activity) and guidance on pharmacological 
interventions (eg, how, which and when different medi-
cation can/should be used). All this will lead to an indi-
vidual care plan for the child. Furthermore, the protocol 
will contain guidance concerning diagnostic testing, treat-
ment and follow-up. The participating practice nurses 
will receive up-to-date retraining in protocolled asthma 
care for children. When new or repeated medication is 
needed, the GP will approve the prescription.
Follow-up visits in the intervention group (both randomised 
and non-randomised)
At baseline and at each control visit, asthma control will 
be determined by the practice nurse using a four-item 
questionnaire based on the Global Initiative for Asthma 
(GINA) guidelines.17
The content and frequency of follow-up visits will 
depend on the asthma control and medication use.
Follow-up schedule for well-controlled patients in the 
intervention group
For well-controlled patients (based on GINA criteria) 
with asthma diagnosed in the previous year, control 
visits will be planned according to the medication used. 
For ‘as needed’ use of SABA, visits will be once in the 
first 3–6 months. When a patient is well controlled and 
with asthma diagnosis of >1 year, the control visit will 
be scheduled annually. When ICS dosage reduction 
in well-controlled patients is attempted (after 1 year of 
well-controlled asthma), control visits will be scheduled 
once every 3 months; at the lowest effective dose once 
every 3–6 months, and after 1 year, annually.
Follow-up schedule for partly controlled/uncontrolled patients 
in the intervention group
Patients with partly or poorly controlled asthma (based on 
GINA criteria) who do not have optimal medication treat-
ment, will receive additional medication according to the 
Dutch guideline (ie, add an ICS, or increase the dosage) 
and will be scheduled for control visits every 2–4 weeks 
until the asthma is well controlled or optimal medication 
treatment is reached. In the starting phase of ICS, control 
visits will be scheduled every 2–4 weeks. When the ICS is 
continued, review visits take place once in every 3 months 
in the first year. Children that remain uncontrolled or 
partly controlled with optimal medication treatment will 
be referred to secondary care. The referred children will 
still receive follow-up in the present study; the parents will 
be requested to continue filling out the electronic ques-
tionnaires and spirometry at t=18 months.
Figure 2 is a flowchart of the therapy and follow-up 
schedule by the practice nurse based on the guidelines of 
both the Dutch College of General Practitioners6 and the 
care guideline for asthma in children.16
Follow-up schedule for the control group
The content and frequency of the control visits for the 
control group (‘usual care’) will be determined according 
to the discretion of the GP.
Setting
The study will take place in academic and non-academic 
GP practices in the south-west region of the Netherlands. 
4300.7802.430. Protected by copyright.
 o
n
 O
ctober 30, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022922 on 27 September 2019. Downloaded from 
5Bousema S, et al. BMJ Open 2019;9:e022922. doi:10.1136/bmjopen-2018-022922
Open access
Figure 2 Flowchart of the therapy and follow-up schedule by the practice nurse. ICS, inhaled corticosteroids; SABA, short-
acting beta agonist.
The academic network of GPs ‘PrimEUR’ in Rotterdam 
and the south-west of the Netherlands consists of 13 GP 
health centres with a total of 150 000 registered patients, 
including ±9000 children aged 6–12 years. This academic 
network aims to excel in training physicians to be GPs, 
to supervise medical students during their internships, 
to initiate healthcare innovation and to participate in 
research in primary care. Moreover, at least 14 (smaller) 
GP practices will be recruited to participate in the study. 
The number of participating GP practices can be enlarged 
by inviting more GPs to participate.
randomisation
The participating health centres (ie, one or more collab-
orating GP practices) will be the units of randomisation. 
They will be randomly assigned to either the intervention 
or control group (‘usual care’) with a 1:1 allocation as per 
a computer-generated stratified randomisation schedule. 
When a practice nurse works for several GP practices, 
all these practices will be part of the same cluster and 
randomised as one group. When a health centre consists 
of several GP practices with their own practice nurse, 
this health centre will also be considered as one cluster. 
When two practice nurses are working in one GP prac-
tice (not separated), this GP practice or health centre will 
be randomised as one cluster. When patients are eligible 
for inclusion in the trial and provide informed consent, 
a researcher will conduct the randomisation using an 
online randomisation programme and the patients will 
be informed in which treatment arm their GP practice 
is randomised. The cluster randomisation is conducted 
within 8 weeks after inclusion of the first patient of that GP 
practice into the present study. All subsequent patients of 
the same cluster will receive the same intervention.
Stratification will be based on the size of the GP prac-
tice and the number of years of experience of the GP. For 
example, GP practices in a single health centre (the same 
postal code) will be randomised in a stratified randomis-
ation of four groups and, therefore, evenly distributed to 
the intervention and the control arm to minimise differ-
ences in baseline characteristics of the patients. A block 
randomisation with varying blocks (ie, 2–6 blocks) will 
be used to equally balance both groups. The sequence 
is kept secret from all researchers involved in the study.
Sample size
To our knowledge, no previous study has determined the 
minimally important difference (MID) for the C-ACT 
for children with asthma in primary care. Therefore, we 
decided to extrapolate the C-ACT score of a previous study 
(that included 166 children aged 6–11 years with asthma 
from secondary care)26 to our sample size calculation.23
Considering an MID of 2, a mean C-ACT score of 19.8 
and with a SD of 4.1,26 a sample size of 126 children will 
be needed to achieve a power of 80% with an alpha of 5%. 
Using an intracluster correlation of 0.0431 and inflating 
the sample size with 15% to take into account expected 
loss to follow-up, the sample size has to increase to 180 
patients.
recruitment
All eligible children aged 6–12 years in the participating 
GP practices will be invited to participate. Eligible patients 
will be selected by searching the electronic patient 
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Figure 3 Flowchart of study procedures. PIF, patient information file.
database of the GPs and applying the inclusion/exclusion 
criteria. Parents will be asked to return a response form.
Study procedures (cluster randomised group)
A researcher (nurse or medical student) will telephone 
the parents to check whether the children are eligible. 
Parents will receive the patient information letter with the 
informed consent form by regular post. When the patient 
and parents are willing to participate, the informed 
consent will be signed by the parents/legal guardians and 
sent to the department of General Practice by post. After 
all the parents of eligible children of one cluster (who are 
willing to participate) have provided informed consent, 
the randomisation is conducted by a researcher and the 
parents are informed (by telephone) in which treatment 
arm their child is allocated. Children who turn 12 years 
during the trial also have to give informed consent. The 
deadline for randomisation is 8 weeks after inclusion of 
the first patient of a cluster. Figure 3 is a flowchart of the 
study procedures.
Study procedures (non-randomised group)
Besides the cluster randomised group of children we will 
include a non-randomised group of children in this trial. 
These children will be recruited in health centres who 
intend to start protocolled nurse-led care for children with 
asthma in their practice. Practice nurses of the non-ran-
domised participating GP practices will attend the same 
training on protocolled asthma care. All eligible children 
who receive protocolled nurse-led care will be invited to 
participate in the non-randomised part of this trial. They 
will be invited by their GP with a slightly adjusted invita-
tion letter, the other study procedures will be identical.
dAtA CollECtIon
Spirometry
A spirometry test will be conducted at the children’s 
homes at baseline and at 18-month follow-up using a 
portable device (CareFusion Vyntus Spiro with Sentry-
Suite Software V.2.21). The spirometry will be conducted 
by two specialised nurses to minimise interobserver bias 
and will be performed according to the guideline of the 
Dutch College of General Practitioners.6 The nurses who 
conduct the spirometry tests will not participate in the 
protocolled care; they will be appointed as independent 
research employees. Reversibility will be determined by 
administering salbutamol via an aerochamber. After the 
spirometry, the nurse will determine whether the test was 
properly conducted. Second, the predicted value of FEV1 
for age, height and gender will be calculated by a tool of 
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the European Respiratory Society. A score of −2 (SD) is 
considered as deviant. If the result of the spirometry indi-
cates less than or equal to −2 SD of FEV1 and the child or 
parents report symptoms such as wheezing or shortness 
of breath, the nurse advises parents to inform the GP of 
the child about the current status of the child. In all other 
cases, to prevent bias, neither the GP nor the parents or 
the child will be informed about the test result.
baseline measurements and questionnaires
Height and weight, asthma,control according to GINA 
guidelines, ethnicity of the child, smoking status of the 
parents and smoking status of the mother during preg-
nancy will be determined during the baseline visit by 
the practice nurse. All these items are entered in an 
online data management system with a secured ‘cloud’ 
(Research Manager, Deventer, the Netherlands).
The other questionnaires: the C-ACT, CHU9D, EQ-5D-Y, 
the questionnaire on satisfaction with delivered care, the 
questionnaire on the frequency/severity of exacerba-
tions and on healthcare costs will be sent to the parents 
(digitally) at baseline and at 3, 6, 12 and 18 months. The 
PAQLQ questionnaire will be sent to the parents only at 
baseline and at 6 and 18 months.
retrospective chart review
Direct and indirect healthcare costs and information on 
co-morbidity will be assessed at 18 months by retrospec-
tive chart review. In the Netherlands, all hospital visits 
(both emergency room visits and cases that are admitted 
to stay in hospital) are reported to the GP; this includes 
the duration of stay. The following items will be assessed: 
referrals from primary to secondary care, number of 
hospital admissions, medication costs, number and dura-
tion of consultations and consultations with the practice 
nurse and/or the physician (for asthma and non-asthma 
related symptoms), evidence of stepping-down therapy 
(ie, reduction in prescribed medication) and information 
on allergies.
Withdrawal of individual participants
Participants can leave the study at any time for any reason 
if they wish to do so, without any consequences. The 
investigator can decide to withdraw an individual from 
the study for any urgent medical reasons.
Analyses
The results of spirometry, the questionnaires and data 
from the retrospective chart review will be entered in an 
online and secured data management system (Research 
Manager). After merging these files, the data will be 
processed with IBM SPSS for Windows software.
Baseline characteristics will be summarised using 
simple descriptive statistics. All analyses will be performed 
according to the intention-to-treat principle. A per-pro-
tocol analysis will also be conducted in patients with 
a maximum ‘no show’ percentage of 33% (1/3 of the 
review visits).
Primary outcome measures
C-ACT scores will be analysed in a multilevel repeated 
measures regression model, which incorporates the 
C-ACT scores for all measurements, including the baseline 
measurement. This method takes into account within-pa-
tient correlation by modelling the covariance structures 
of the residuals per measurement. Several structures will 
be considered, starting with the unstructured covariance 
structure.
The differences in C-ACT scores between the two 
groups will be modelled by the interaction of treatment 
and measurement after baseline, assuming that any differ-
ence in C-ACT at baseline is due to chance. Additional 
variables will be considered for inclusion in the regres-
sion model if they are substantially different at baseline 
or if they are expected to be predictive of drop-out at a 
later stage.
Furthermore, a subgroup analysis will be conducted 
in which the total sample is divided into three groups 
according to their baseline characteristics; a group with 
insufficient asthma control (undertreated children), a 
group with sufficient asthma control and continuous ICS 
use (possible overtreated children) use and a group with 
the remaining children.
Secondary outcome measurements
Differences in C-ACT scores within a study subject 
(subjects in the non-randomised group of protocolled 
nurse led care), will be estimated with a paired Z-test or 
paired t-test. Besides we will determine differences in 
outcome between the randomised and non-randomised 
protocolled nurse-led care samples and the usual care 
group by using unpaired t-test in case of normally distrib-
uted values and Mann-Whitney U test in case of non-nor-
mally distributed values. For categorical outcomes, we will 
use Chi-square test for statistical analyses.
Missing data
The multilevel regression model also deals with missing 
observations of the outcome measure by exploiting the 
fact that observations within patients are correlated, if the 
missingness occurs completely at random or at random 
(conditional on the observed data in the model). This 
allows unbiased estimation of regression coefficients 
and to make optimal use of all available data, even when 
some measurements are missing.32 Dropouts or missing 
visits will be reviewed to identify possible informative 
missingness.
Secondary outcome measures
The numbers of exacerbations will be analysed in Pois-
son-type regression models, with the time spent in 
the study as offset, thus adjusting for potential loss to 
follow-up. The other secondary outcome measures, that is, 
generic quality of life (measured by CHU9D and EQ-5D), 
disease-specific quality of life (PAQLQ), satisfaction and 
3-monthly costs will be analysed in separate multilevel 
regression models. The probability of achieving asthma 
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control at any moment in time will be analysed in a multi-
level logistic regression model. Asthma control is defined 
as a C-ACT score of 20 or better.
Economic evaluation
A prospective economic evaluation will be performed 
from both a healthcare perspective and a societal perspec-
tive alongside the clinical trial, according to Dutch and 
international guidelines.33 34 If nurse-led asthma care 
leads to more costs, as well as health gains compared with 
usual care, the cost-effectiveness will be expressed in the 
following incremental cost-effectiveness ratios (ICERs):
 ► Costs per quality-adjusted life year (QALY).
 ► Costs per additional patient with asthma control.
The uncertainty around the estimates of incremental 
costs and effects, and around the ICERs, will be displayed 
on cost-effective planes and in cost-effectiveness accepta-
bility curves.
Costs are calculated by measuring all relevant cost cate-
gories per interval at the patient level and multiplying 
natural units by standard prices. The costs are then anal-
ysed in a multilevel repeated measures regression model. 
Based on the regression results, adjusted average costs 
per interval and for the total study period are calculated 
for each treatment option. The healthcare perspective 
includes all medical costs (GP and nurse contacts, hospital 
admissions, pulmonologist or paediatrician consulta-
tions, medication). The societal perspective also includes 
the costs of parent’s production losses as a consequence 
of their child’s asthma.
The QALY calculations are based on the results of the 
regression analysis of the generic quality-of-life measure-
ments (EQ-5D-Y and CHU-9D). The results are used to 
calculate adjusted average quality of life at the end of each 
interval for each treatment. After this, QALYs per interval 
can be calculated by taking the average of two measurements 
around the interval and multiplying this by the duration.
The results of a multilevel logistic regression analysis will 
be used to calculate individual and average probabilities of 
achieving asthma control at t=18 for each treatment. The 
costs per additional patient with asthma control can then 
be calculated as the ratio of the incremental costs and the 
difference of the average probabilities.
SAFEty rEPortIng
Monitoring
In accordance with the Dutch Act on Medical Research 
Involving Human Subjects (the WMO; section 10, subsec-
tion 4), the sponsor will suspend the study when there is 
sufficient ground that continuation of the study will jeop-
ardise a participant’s health or safety. The sponsor will 
notify the accredited Medical Ethical committee (MEC) 
without undue delay of a temporary halt, including the 
reason for such an action. The study will be suspended 
pending a further positive decision by the accredited 
MEC. The investigator will ensure that all participants are 
kept adequately informed.
Due to the characteristics of this study, it is not neces-
sary to install a Data Safety Monitoring Board. Never-
theless, the study will be monitored as described in the 
ICH-GCP Guidelines (Chapter 5.18). The department of 
general practice has developed a monitoring plan and a 
monitoring checklist (based on the ICH-GCP Guidelines) 
which will be used during this study.
Adverse events
Serious adverse events (SAEs) will probably be first 
observed by the treating GP. A serious adverse event is any 
undesired medical occurrence that is lethal, life-threat-
ening, requires hospitalisation or prolongation of 
existing inpatients’ hospitalisation, results in persistent or 
significant disability or incapacity, results in a congenital 
anomaly or birth defect or a undesired medical occur-
rence which was adequately diverted before serious harm 
occurred.
The GP is asked to report any SAE to the investigator. In 
addition, patients will be asked if they have been admitted 
to hospital when they answer the questionnaires every 
3–6 months. Patients will be contacted by the researcher 
if they have been admitted to hospital. The investigators 
will process the SAE and report it through a web portal 
and to the accredited MEC.
Amendments
Amendments are changes made to the research protocol 
after a favourable opinion from the accredited MEC. All 
substantial amendments will be notified to the MEC and 
to the competent authority.
Ethics and dissemination
All data will be obtained, managed and monitored 
according to the guidelines of good clinical practice. This 
study was approved by the Medical Ethics committee of 
the Erasmus Medical Center Rotterdam, the Netherlands 
(MEC-2017–566). Findings of the study will be published 
in international journals and presented at international 
conferences. Where appropriate, the results of this study 
can be directly implemented in the revisions of the guide-
lines. The researchers are in close contact with policy-
makers, the Dutch GP-guideline organisation and local 
organisations that are willing to implement the interven-
tion on a large scale when proven effective.
Patient involvement
We created will created a panel of two parents of children 
with asthma. These parents were involved in conducting the 
patient information brochure concerning the study. They 
were also asked to assess the design of the study and the 
burden of the intervention for their children and family.
dISCuSSIon
The aim of this study is to determine whether protocolled 
practice nurse-led asthma care for children aged 6–12 years 
in primary care provides more effective asthma control 
than usual care. This age category was selected because an 
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asthma diagnosis is difficult to confirm in children aged 
≤6 years. In ≥50% of preschool children who experience at 
least one episode of wheezing before age 3 years, the symp-
toms will not persist and they will not develop asthma later 
in life.6 Moreover, we think that children aged 6–12 years 
are more willing to follow the advice of their parents, so 
that they may derive more benefit from the intervention 
than older, more independent, teenagers. With the intro-
duction of individual care plans and education about 
pathophysiology, prevention and medication, children and 
their parents may learn to influence their chronic disease 
in a more positive way. This could result in better asthma 
control and might improve the quality of life of children 
and their family members. These are the reasons for the 
selection of children aged 6–12 years for this trial.
Asthma in children is a clinical diagnosis for which no 
‘gold standard’ diagnostic criteria are available. Since 
different definitions of asthma are reported in national/
international guidelines,6 7 16 17 35 this makes difficult to 
present a clear definition for enrolment in the present trial. 
However, all definitions include the presence of symptoms 
(eg, more than one of: wheeze, breathlessness, chest tight-
ness, cough) and of variable airflow obstruction. Airway 
inflammation is also a frequent characteristic. However, 
fractional exhaled nitric oxide (FeNO) and eosinophilia 
measurements are not of added value in the diagnostic 
process and follow-up of children with asthma.7 There-
fore, these latter tests are not recommended in the current 
primary and secondary care guidelines for Dutch GPs.6 7 
Moreover, this would entail conducting additional invasive 
tests (such as blood sampling) in the children; therefore, 
FeNO and eosinophilia will not be determined in the 
present trial.
The guideline of the Dutch College of General Practi-
tioners offers the following definition: ‘asthma is a clinical 
diagnosis that may be supported by the results of a spirom-
etry test.6 Wheezing is the core symptom of asthma’.6 The 
selection of eligible children is based on the registered 
diagnosis in the patient file; International Classification of 
Primary Care (ICPC) code and/or the use of medication 
in the previous year. However, this method could result in 
the selection of children who do not use the medication, 
despite the prescription. Nevertheless, a registered diag-
nosis, also referred to as ‘physician-diagnosed asthma’ has 
been used as an inclusion criterium in other trials.11 36 37 
For our study, we considered asthma to be present in the 
children, when they were prescribed an ICS (>one time) 
or salbutamol or terbutaline (>two times) in the previous 
year or had only one prescription of salbutamol or terbu-
taline in the previous year and a registered ICPC code for 
asthma (R96) or R29.02 ‘Prikkelbare luchtwegen’ (bron-
chial spasm) . We think this is a sufficient indication for 
the presence of asthma.
Some questionnaires have been validated to deter-
mine asthma control in the paediatric population. For 
example, the Asthma Control Questionnaire (ACQ)38 
and the C-ACT26 are frequently used in international 
trials.17 26 27 38–41 Both questionnaires show good agreement 
as compared with the GINA criteria.40 The ACQ is a valid 
instrument for measuring asthma control in children 
aged 6–16 years. It consists of six symptom questions with 
a recall of 1 week; however, for children aged 6–10 years, 
it must be administered by a trained interviewer.42 In the 
present trial, the questionnaires will be sent by email, 
since it is not feasible to arrange face-to-face contacts for 
all the study measurements.
Furthermore, no validated Dutch version of the inter-
viewer administered ACQ is available. Lastly, we assume 
that children might prefer the C-ACT, since a visual scale 
with expressed emotions is shown after the questions to 
help the child determine the correct answer. Therefore, 
the ACQ is less appropriate than the C-ACT to determine 
asthma control in the children in this study.
In the present study, two spirometry tests will be 
conducted. Reversibility will be tested by administering the 
SABA ‘salbutamol’ (inhalation medication). The dosage of 
salbutamol will be according to the guideline of the Dutch 
College of General Practitioners.6 Possible side effects 
include tremor of the hands, headache, peripheral vasodi-
latation and an increase of heart rate.6 However, generally, 
these symptoms only occur when salbutamol is used in a 
higher dosage. In this proposed trial, the maximum dosage 
will never be exceeded. Also, the parents of the child will 
be asked to cease use of airway dilators before the test; this 
could lead to a temporary increase of the symptoms of 
asthma. However, this is a standard procedure for spirom-
etry6 and, of course, when it is not possible or medically irre-
sponsible to stop inhalation medication at that moment, 
spirometry will be postponed.
The participating child, parents, practice nurse and GP 
will be informed about the results of the spirometry only 
when the FEV1 is less than or equal to −2 SD of predicted 
value for age, height and gender. In this case of severe 
obstruction of the lungs, it would be unethical not to inform 
them and provide the GP the opportunity to improve the 
medical condition of the child. If the results are shared in 
other cases, there is a risk of increased healthcare consump-
tion because of more awareness of the condition or worries 
of the parents or GP. This could result in bias, because extra 
review visits (especially in the usual care arm) could be 
planned, which could lead to better asthma control.
The randomisation of the intervention (the practice 
nurse or group of practice nurses) will be conducted 
by stratified cluster randomisation. A pragmatic trial 
compares the effectiveness of an intervention in everyday 
practice with relatively unselected participants and under 
flexible conditions. Pragmatic trials have a high external 
validity due to the relatively unselected patients and are, 
therefore, helpful to answer the question whether the 
intervention has additional value in real practice.43 The 
aim of the current pragmatic trial is to compare proto-
colled nurse-led care by the practice nurse to the usual 
care of the GP. Cluster randomised trial designs are 
common in pragmatic research.44–46 Cluster randomised 
trials have particular utility in effectiveness and imple-
mentation studies. This design is appropriate for the 
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evaluation of interventions that are naturally applied at 
cluster level, for example, general practices that opted for 
a certain stepped approach. Moreover, cluster randomis-
ation avoids group contamination. Disadvantages of prag-
matic cluster randomised trials are the generalisability 
and the recruitment bias; however, this can be (partly) 
solved by inviting all eligible patients from a cluster to 
participate in the trial. Another issue with cluster rando-
misation is the possible baseline imbalance between the 
randomised groups; however, this bias can be minimised 
by stratification of the clusters.
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